Volume 25, Number 10—October 2019
Research
Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
Table 2
Name | Recombinant spike protein–based indirect immunofluorescence test, reciprocal endpoint titers* |
|||||
---|---|---|---|---|---|---|
HCoV-229E | HCoV-NL63 | HCoV-OC43 | HCoV-HKU1 | SARS-CoV | MERS-CoV | |
WHO/A | 160 | 1,280 | 320 | 640 | NR | NR |
WHO/B | 2,560 | 1,280 | 1,280 | 160 | NR | NR |
WHO/C | 160 | 320 | 1,280 | 320 | NR | NR |
WHO/D | 1,280 | 2,560 | 320 | 160 | NR | NR |
WHO/E | 320 | 1,280 | 160 | 160 | NR | NR |
WHO/F | 80 | 320 | 320 | 160 | NR | NR |
WHO/G | 320 | 320 | 1,280 | 1,280 | NR | NR |
*All serum samples were tested in a dilution range of 1:20 to 1:5,120. CoV, coronavirus; HCoV, human CoV; MERS, Middle East respiratory syndrome; NR, nonreactive at the cutoff serum dilution of 1:20; SARS, severe acute respiratory syndrome; WHO, World Health Organization.
1Study participants who contributed data are listed at the end of this article.
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.